These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 25082210)
61. Paclitaxel and naringenin-loaded solid lipid nanoparticles surface modified with cyclic peptides with improved tumor targeting ability in glioblastoma multiforme. Wang L; Wang X; Shen L; Alrobaian M; Panda SK; Almasmoum HA; Ghaith MM; Almaimani RA; Ibrahim IAA; Singh T; Baothman AA; Choudhry H; Beg S Biomed Pharmacother; 2021 Jun; 138():111461. PubMed ID: 33706131 [TBL] [Abstract][Full Text] [Related]
62. Development, Optimization, and Evaluation of Carvedilol-Loaded Solid Lipid Nanoparticles for Intranasal Drug Delivery. Aboud HM; El Komy MH; Ali AA; El Menshawe SF; Abd Elbary A AAPS PharmSciTech; 2016 Dec; 17(6):1353-1365. PubMed ID: 26743643 [TBL] [Abstract][Full Text] [Related]
63. Chitosan-functionalized lipid-polymer hybrid nanoparticles for oral delivery of silymarin and enhanced lipid-lowering effect in NAFLD. Liang J; Liu Y; Liu J; Li Z; Fan Q; Jiang Z; Yan F; Wang Z; Huang P; Feng N J Nanobiotechnology; 2018 Sep; 16(1):64. PubMed ID: 30176941 [TBL] [Abstract][Full Text] [Related]
64. Trimethyl chitosan based conjugates for oral and intravenous delivery of paclitaxel. He R; Yin C Acta Biomater; 2017 Apr; 53():355-366. PubMed ID: 28189812 [TBL] [Abstract][Full Text] [Related]
65. Brain targeted solid lipid nanoparticles for brain ischemia: preparation and in vitro characterization. Morsi NM; Ghorab DM; Badie HA Pharm Dev Technol; 2013; 18(3):736-44. PubMed ID: 23477526 [TBL] [Abstract][Full Text] [Related]
66. Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: enhanced intestinal absorption and lymphatic uptake. Cho HJ; Park JW; Yoon IS; Kim DD Int J Nanomedicine; 2014; 9():495-504. PubMed ID: 24531717 [TBL] [Abstract][Full Text] [Related]
67. Formulation and Evaluation of Neuroactive Drug Loaded Chitosan Nanoparticle for Nose to Brain Delivery: In-vitro Characterization and In-vivo Behavior Study. Qureshi M; Aqil M; Imam SS; Ahad A; Sultana Y Curr Drug Deliv; 2019; 16(2):123-135. PubMed ID: 30317997 [TBL] [Abstract][Full Text] [Related]
68. Ethyl oleate-containing nanostructured lipid carriers improve oral bioavailability of trans-ferulic acid ascompared with conventional solid lipid nanoparticles. Zhang Y; Li Z; Zhang K; Yang G; Wang Z; Zhao J; Hu R; Feng N Int J Pharm; 2016 Sep; 511(1):57-64. PubMed ID: 27374194 [TBL] [Abstract][Full Text] [Related]
69. A comparison study of lipid and polymeric nanoparticles in the nasal delivery of meloxicam: Formulation, characterization, and in vitro evaluation. Akel H; Ismail R; Katona G; Sabir F; Ambrus R; Csóka I Int J Pharm; 2021 Jul; 604():120724. PubMed ID: 34023443 [TBL] [Abstract][Full Text] [Related]
70. Nasal vaccination with r4M2e.HSP70c antigen encapsulated into N-trimethyl chitosan (TMC) nanoparticulate systems: Preparation and immunogenicity in a mouse model. Dabaghian M; Latifi AM; Tebianian M; NajmiNejad H; Ebrahimi SM Vaccine; 2018 May; 36(20):2886-2895. PubMed ID: 29627234 [TBL] [Abstract][Full Text] [Related]
71. Development and in vitro characterization of chitosan-coated polymeric nanoparticles for oral delivery and sustained release of the immunosuppressant drug mycophenolate mofetil. Mohammed M; Mansell H; Shoker A; Wasan KM; Wasan EK Drug Dev Ind Pharm; 2019 Jan; 45(1):76-87. PubMed ID: 30169982 [TBL] [Abstract][Full Text] [Related]
72. Promises of a biocompatible nanocarrier in improved brain delivery of quercetin: Biochemical, pharmacokinetic and biodistribution evidences. Kumar P; Sharma G; Kumar R; Singh B; Malik R; Katare OP; Raza K Int J Pharm; 2016 Dec; 515(1-2):307-314. PubMed ID: 27756627 [TBL] [Abstract][Full Text] [Related]
73. Development of Domperidone Solid Lipid Nanoparticles: In Vitro and In Vivo Characterization. Shazly GA; Alshehri S; Ibrahim MA; Tawfeek HM; Razik JA; Hassan YA; Shakeel F AAPS PharmSciTech; 2018 May; 19(4):1712-1719. PubMed ID: 29532427 [TBL] [Abstract][Full Text] [Related]
74. In Vitro and Ex Vivo Evaluations of Lipid Anti-Cancer Nanoformulations: Insights and Assessment of Bioavailability Enhancement. Jain AS; Dhawan VV; Sarmento B; Nagarsenker MS AAPS PharmSciTech; 2016 Jun; 17(3):553-71. PubMed ID: 27068527 [TBL] [Abstract][Full Text] [Related]
75. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery. Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762 [TBL] [Abstract][Full Text] [Related]
76. Synthesis and characterization of curcumin loaded polymer/lipid based nanoparticles and evaluation of their antitumor effects on MCF-7 cells. Kumar SS; Mahesh A; Mahadevan S; Mandal AB Biochim Biophys Acta; 2014 Jun; 1840(6):1913-22. PubMed ID: 24440669 [TBL] [Abstract][Full Text] [Related]
77. Effect of a Solid Lipid Nanoparticle Formulation on the Bioavailability of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine After Oral Administration. Valdes SA; Alzhrani RF; Lansakara-P DSP; Cui Z AAPS PharmSciTech; 2020 Jan; 21(3):77. PubMed ID: 31970527 [TBL] [Abstract][Full Text] [Related]
79. Design and evaluation of a novel potential carrier for a hydrophilic antitumor drug: Auricularia auricular polysaccharide-chitosan nanoparticles as a delivery system for doxorubicin hydrochloride. Xiong W; Li L; Wang Y; Yu Y; Wang S; Gao Y; Liang Y; Zhang G; Pan W; Yang X Int J Pharm; 2016 Sep; 511(1):267-275. PubMed ID: 27424168 [TBL] [Abstract][Full Text] [Related]
80. Pharmacokinetics, tissue distribution and relative bioavailability of geniposide-solid lipid nanoparticles following oral administration. Wang F; Cao J; Hao J; Liu K J Microencapsul; 2014; 31(4):382-9. PubMed ID: 24697172 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]